Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments. Romi Gupta
Trends Immunol. 2025 Jan 23:S1471-4906(24)00308-9. doi: 10.1016/j.it.2024.12.006. Online ahead of print. ABSTRACT Ovarian cancer (OC) is the most lethal gynecologic malignancy, characterized by multiple histological subtypes, each with distinct pathological and clinical features. Current treatment approaches include cytotoxic chemotherapies, poly(ADP-ribose) polymerase (PARP) inhibitors, bevacizumab, hormonal therapy, immunotherapy, and antibody-drug conjugates (ADCs). In this review we … Read more